Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$767,328Cash on Hand
3.9mo Cash Runway
Follow ADXN by emailGet an email when ADXN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ADXN, unsubscribe in one click. Privacy
📣 What ADXN Says Is Next
fourth quarter of 2027 · “The Group expects that its existing cash and cash equivalents at the issuance date of these unaudited interim condensed consolidated financial statements will be sufficient to fund its operations and meet all of its obligations as they fall due through the fourth quarter of 2027.”
Company press release, Sep 28, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Financing Addex's spin-out Neurosterix closed a $105 million Series B financing, with proceeds mainly for Phase 2 development of NTX-253, an M4 PAM for schizophrenia. Addex did not participate, and its stake is now 8.5% at a valuation of $18.6 million. Form 6-K · SEC filing · Press release
Oct 29, 2026 ·
Financing Addex issued 93,000,000 new registered shares at a nominal value of CHF 0.01, fully subscribed by its wholly-owned subsidiary Addex Pharma S.A., to create treasury shares for future financing flexibility. Issued share capital rose to CHF 3,116,544.96 (311,654,496 shares), while outstanding shares are unchanged. Form 6-K · SEC filing · Press release
Oct 8, 2026 ·
Clinical trial Spin-out Neurosterix completed Phase 1 studies of NTX-253, an oral M4 PAM for schizophrenia, and plans to advance it into Phase 2 patient studies. Addex holds a 20% equity interest in Neurosterix. Form 6-K · SEC filing · Press release
Oct 2, 2026 ·
Leadership Addex Therapeutics appointed Jean-Philippe Rocher as Head of Pharmaceutical Development and member of Executive Management, a return to the company. Mikhail Kalinichev stepped down as Head of Translational Science to focus on his role at Neurosterix. Form 6-K · SEC filing · Press release
Sep 28, 2026 ·
Addex Therapeutics furnished a 6-K for the period ended June 30, 2026, with exhibits incorporated by reference into its Form F-3 and Form S-8 registration statements. The cover text itself reports no results, deal or regulatory action. Form 6-K · SEC filing · Press release
Sep 25, 2026 ·
Deal Addex Therapeutics regained full global rights to its GABAB positive allosteric modulator assets from Indivior UK Limited after Indivior rationalized its R&D and announced a planned merger of its parent with Supernus Pharmaceuticals. Form 6-K · SEC filing · Press release
Aug 26, 2026 ·
Financing Addex raised USD 2.8 million (CHF 2.2 million) by selling 437,869 ADSs, representing 52,544,280 shares, through its ATM agreement with H.C. Wainwright & Co. The company says this extends its cash runway to the fourth quarter of 2027. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Oct 2022 · Phase 2 · Results Expected · Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm Registry primary completion date, not a results date
Feb 2012 · Phase 2 · Results Expected · ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease Registry primary completion date, not a results date
Dec 2009 · Phase 2 · Results Expected · ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD) Registry primary completion date, not a results date
Oct 2009 · Phase 2 · Results Expected · ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD) Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ADXN holds $767,328 in cash and short-term investments and burns about $596,668/quarter from operations,
an estimated runway of 3.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:87 · High
Cash runway 4 months +40
ATM program on file since Dec 2025 +15
Shelf registration (F-3, Nov 2025) +10
Going-concern doubt in the latest 20-F +15As stated in Note 4, these events or conditions, along with other matters as set forth in Note 4, raise substantial doubt about the Group’s ability to continue as a going concern.20-F, May 2026
Share count 147,831,814 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ADXN picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ADXN and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.